Precision Peptide plans non-brokered private placement of up to 4,000,000 shares at $0.5 each, targeting up to $2 million gross proceeds

  • The Precision Peptide Company launched a non-brokered private placement of 3,000,000 to 4,000,000 common shares at $0.5 each.
  • Gross proceeds targeted at $1.5 million to $2 million.
  • Net proceeds earmarked for working capital, marketing, inventory, and products.
  • Closing expected on or about June 25, 2026, with the financing potentially completed in tranches.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Precision Peptide Company Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202606111700NEWSFILECNPR____20260611_301183_1) on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.